Madrigal Pharmaceuticals (MDGL) Other Non-Current Assets (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Other Non-Current Assets of $23.5 million for Q1 2026, up 369.96% year-over-year from $5.0 million in Q1 2025, and up 369.96% quarter-over-quarter from $5.0 million in Q3 2025.
Madrigal Pharmaceuticals (MDGL) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 9 years of Other Non-Current Assets data on file, last reported at $23.5 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $23.5 million, up 369.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.5 million (up 369.96% YoY), and the FY2024 annual result was $5.0 million, changed N/A from the prior year.
- Other Non-Current Assets grew to $23.5 million in Q1 2026 per MDGL's latest filing, from $5.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $23.5 million in Q1 2026 and troughed at $5.0 million in Q2 2024.
- A 3-year average of $7.6 million and a median of $5.0 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets changed 0.0% in 2025, then jumped 369.96% in 2026.
- A 3-year view of Other Non-Current Assets shows it stood at $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then jumped by 369.96% to $23.5 million in 2026.
- Business Quant data shows MDGL's Other Non-Current Assets at $23.5 million in Q1 2026, $5.0 million in Q3 2025, and $5.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | 23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.50 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Sep 30, 2015 | 226,000.00 |
| Jun 30, 2015 | 278,000.00 |
| Mar 31, 2015 | 564,000.00 |
| Dec 31, 2014 | 305,000.00 |
| Sep 30, 2014 | 331,000.00 |
| Jun 30, 2014 | 358,000.00 |
| Mar 31, 2014 | 384,000.00 |
| Dec 31, 2013 | 1.41 Mn |
| Sep 30, 2013 | 433,000.00 |
| Jun 30, 2013 | 464,000.00 |
| Mar 31, 2013 | 481,000.00 |
| Dec 31, 2012 | 458,000.00 |
| Sep 30, 2012 | 466,000.00 |